|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,684.00 DKK | -1.66% |
|
-4.83% | -16.92% |
| 05-12 | Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target | FW |
| 05-11 | Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy | FW |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 3.69B | 25.89% | 28.63% | 17.53% | 9.99% | -1.51x | |
| 4.23B | 30.41% | 24.81% | 20.15% | 17.36% | -3.18x | |
| 6.5B | 42.13% | 52.64% | 28.56% | 20.88% | -0.99x | |
| 606M | -210.54% | -205.59% | -249.28% | - | 0.72x | |
| 3.37B | -39.59% | -48.95% | -5.88% | -5.1% | 6.99x | |
| 3.12B | 22.53% | 31.44% | 11.9% | 8.13% | -1.19x | |
| 437M | -36.42% | -29.57% | -7.45% | -4.07% | 6.67x | |
| 294M | -18.56% | -24.05% | -9.34% | -9.05% | 6.63x | |
| 2.32B | 33.73% | 37.59% | 35.53% | 27.02% | -1.18x | |
| 958M | -30.08% | -31.31% | -42.49% | - | 2.15x | |
| 829M | -0.2% | 11.86% | -0.5% | - | -6.61x | |
| 88.04M | -891.6% | -695.44% | - | -55.55% | 0.05x | |
| 463M | 21.89% | 3.81% | 25.37% | 11.13% | 2.25x | |
| 1.16B | 23.46% | 22.49% | 20.46% | 11.16% | 0.73x | |
| 113M | -310.18% | -226% | - | - | - | |
| 498M | 32.27% | 31.52% | 16.97% | 14.74% | -3.83x | |
| Average | 1.79B | -81.55% | -63.51% | -9.89% | 3.89% | 0.51x | |
| Weighted average by Cap. | 2.82B | -45.35% | -35.12% | -12.36% | 8.7% | 0.16x |
- Stock Market
- Equities
- GMAB Stock
- Sector Genmab A/S
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition